Prevail Therapeutics Inc.

Prevail Therapeutics Inc. operates as a gene therapy company that focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s product includes PR001, which is in a Phase I/II clinical trial for the treatment of Parkinson’s disease with the GBA1 mutation and neuronopathic Gaucher disease. Furthermore, it also develops PR006 for the treatment of frontotemporal dementia with GRN mutations and PR004 for the treatment of synucleinopathies. The company was incorporated in 2017 and is based in New York, New York. As of January 22, 2021, Prevail Therapeutics Inc. operates as a subsidiary of Eli Lilly and Company.